The Japanese Ministry of Health, Labor and Welfare has granted conditional and time-limited marketing authorization to two regenerative medical products derived from reprogrammed iPS cells, marking a significant milestone in the development of new treatments.
A Major Step Forward for Regenerative Medicine
Exactly 20 years have passed since the creation of mouse iPS cells by Shinya Yamanaka, director emeritus of the iPS Cell Research Institute at Kyoto University. This breakthrough has paved the way for the development of regenerative medicine products that can be used to treat a range of diseases and conditions.
ReHeart: A Novel Treatment for Severe Heart Failure
One of the approved products is ReHeart, developed by Qualipse, a startup based at Osaka University. This sheet of specialized heart cells called cardiomyocytes differentiated from iPS cells of healthy donors aims to improve the lives of patients with severe heart failure due to ischemic cardiomyopathy.
Severe heart failure is a serious condition that worsens over time, and current treatment options are limited. ReHeart addresses this unmet medical need by increasing blood flow and repairing tissue through signaling proteins secreted by the transplanted cells. In a national multicenter collaborative study involving eight patients with severe heart failure, a trend toward improvement was confirmed in four patients, with peak oxygen consumption (VO2 peak) increasing by more than 10 percent at 52 weeks post-transplant.
Amusepri: A New Treatment Option for Parkinson’s Disease
The second approved product is Amusepri (generic name: laguneprocell), developed by Sumitomo Pharma and Racthera. This product consists of precursor cells destined to become dopamine-producing neurons made from donor iPS cells, aimed at improving motor symptoms in patients with Parkinson’s disease who have had an inadequate response to existing drug therapies.
Parkinson’s disease is a neurodegenerative disorder that causes motor symptoms such as tremors and muscle rigidity due to the gradual loss of dopaminergic nerve cells in the brain. Amusepri aims to offer a new treatment option by transplanting progenitor cells from lost dopamine-making neurons directly into the brain, improving off-time scores on the Motor Symptoms Diagnostic and Treatment Rating Scale (MDS-UPDRS Part III) 24 months after transplantation.
The Japanese System: Enabling Early Approval in Regenerative Medicine
The approval process for these products is unique to Japan, where a comprehensive system has been established to facilitate the development of regenerative medicine. This includes long-term public funding from national institutions, which has enabled early approval in fields such as regenerative medicine, where large-scale clinical trials are difficult to conduct.
A Future Filled with Promise
The approval of these products marks a significant milestone in the development of new treatments for patients with severe heart failure and Parkinson’s disease. As researchers continue to accumulate long-term data and refine their technologies, the potential for regenerative medicine to transform patient outcomes is vast.
Conclusion
In conclusion, Japan’s regenerative medicine breakthrough marks a major step forward in the development of new treatments for patients with severe heart failure and Parkinson’s disease. As the world continues to move forward with caution and scientific rigor, the potential for these products to transform patient outcomes is significant.
References
- Ministry of Health, Labor and Welfare, Japan: “Regenerative Medicine” (2023)
- Qualipse: “ReHeart” (2023)
- Sumitomo Pharma and Racthera: “Amusepri” (2023)
- Kyoto University iPS Cell Research Foundation: “iPS Cells” (2023)
© 2026 Condé Nast. All rights reserved.